Labelling & Naming – EBG Perspective, DIA Berlin 2014

3 December 2014

Policy

WHO BQ Proposal – EGA’s perspective, 59th INN Consultation, WHO, Geneva, 14 October 2014

14 October 2014

Policy

GfK – Factors Supporting a Sustainable European Biosimilar Medicines Market

9 September 2014

Report

A study about the future sustainability of the biosimilar medicines […]

EMA mAb Workshop – Guideline on Similar Biological Medicinal Products

31 October 2013

Policy, Video

EMA mAb Workshop – Quality Target Product Profile in the Development of a Biosimilar

31 October 2013

Policy, Video

EMA mAb Workshop – Stepwise Approach to Non-Clinical Program

31 October 2013

Policy, Video

International Generic Pharmaceutical Alliance (IGPA) Letter Regarding TGA Guidance Titled “Evaluation of Biosimilars”, 2013

18 September 2013

Policy

Safe Prescription,Safe Dispensing, Identification and Track&Trace of All Biologicals in the Context of the Re-opened Biosimilars INN Debate – 11th EGA Symposium on Biosimilar Medicines, Suzette Kox, London 2013

25 April 2013

Policy

Biosimilar Monoclonal Antibodies – 11th EGA International Symposium on Biosimilar Medicines, Gudbjorg Edda Eggertsdottir, London, 25 April 2013

25 April 2013

Policy

Production and Control of Biosimilars versus Innovators, Biosimilars Present and Future – Da Silva, Infarmed, Lisbon, 3 April 2013 (PPT)

3 April 2013

Policy